Precipio, Inc ticker symbol PRPO is a penny stock that I have invested in and feel is a good time to be investing in so I just added more to my holdings. It recently just launched the ”first lung cancer treatment resistance panel specifically for the critical mutations T790M and C797S in the EGFR gene. The test will use Precipio’s patented ICE-COLD PCR™ liquid biopsy enrichment technology to enable better cancer outcomes by identifying treatment resistance mutations in non-small cell lung cancer (NSCLC).” At .73 the stock price is near it’s 52 week low of .59 with a market cap of approximately 9 million.
In a news release today “within the first half of Q1-2018 it has set up trials for pathology lab services with 4 times as many new oncology customers as in the entire prior quarter, representing a substantial increase of its new customer rate to 10 trials in the first half of Q1-2018”, so they may possibly be close to experience critical mass with large upside potential. The company is based in New Haven, Connecticut. You can check out their website for more info at http://www.precipiodx.com. Please remember these penny stocks are risky and a bit of gamble and please do your own due diligence. Personally, I don’t invest more than I can lose. This is for informational purposes only and I am not affiliated with the company in any way.
References:
New test fulfills promise of liquid biopsies to cost effectively monitor patients, 2018, http://client.irwebkit.com/precipiodx/news/2441716
Yahoo Finance, Precipio Inc., PRPO, 2018, https://finance.yahoo.com/quote/PRPO?p=PRPO